Evidence map›Paper›PMID 37359062›Full record

ArticlePublic health action2023

Scoring tools to identify TB patients facing catastrophic costs in the Philippines.

T Yamanaka, A M C Garfin, D M G Gaviola, R M Arao, F Morishita, T Hiatt, N Nishikiori, R P Yadav

Abstract read
In one paragraph

Article in Public health action, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

T YamanakaWorld Health Organization (WHO), Global Tuberculosis Programme, Geneva, Switzerland.
A M C GarfinNational TB Control Programme, Department of Health, Manila, The Philippines.
D M G GaviolaNational TB Control Programme, Department of Health, Manila, The Philippines.
R M AraoHealth Policy Development Programme (HPDP) UPecon Foundation, Inc., Quezon City, The Philippines.
F MorishitaWHO Regional Office for the Western Pacific, Manila, The Philippines.
T HiattWHO Country Office, Manila, The Philippines.
N NishikioriWorld Health Organization (WHO), Global Tuberculosis Programme, Geneva, Switzerland.
R P YadavWHO Country Office, Manila, The Philippines.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundThis study was to meet a practical need to design a simple tool to identify TB patients who may potentially be facing catastrophic costs while seeking TB care in the public sector. Such a tool may help prevent and address catastrophic costs among individual patients.

methodsWe used data from the national TB patient cost survey in the Philippines. We randomly allocated TB patients to either the derivation or validation sample. Using adjusted odds ratios (ORs) and β coefficients of logistic regression, we developed four scoring systems to identify TB patients who may be facing catastrophic costs from the derivation sample. We validated each scoring system in the validation sample.

resultsWe identified a total of 12 factors as predictive indicators associated with catastrophic costs. Using all 12 factors, the β coefficients-based scoring system (area under the curve [AUC] 0.783, 95% CI 0.754-0.812) had a high validity. Even with seven selected factors with OR > 2.0, the validity remained in the acceptable range (β coefficients-based: AUC 0.767, 95% CI 0.737-0.798).

conclusionThe β coefficients-based scoring systems in this analysis can be used to identify those at high risk of facing catastrophic costs due to TB in the Philippines. Operational feasibility needs to be investigated further to implement this in routine TB surveillance.

Indexed as

predictive valuerisk assessmentTB costsThe Philippinestuberculosis

Identifiers

PMID37359062
PMCPMC10290262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.